Manufacturer
XEPA-SOUL PATTINSON (MALAYSIA) SDN BHD
Contents
Each 5 mL of oral susp contains sulfamethoxazole 200 mg and trimethoprim 40 mg
Indication
Acute exacerbations of chronic bronchitis, Acute otitis media, Urinary tract infections, Pneumocystis (carinii) jirovecii pneumonia, Prophylaxis of Pneumocystis(carinii) jirovecii pneumonia
Instruction
960 mg once daily for 7 days; 960 mg once daily 3 times wkly on alternate days; or 960 mg bid 3 times wkly on alternate days.
Drug interaction
May increase risk of hyperkalaemia w/ ACE inhibitors. Increased risk of methaemoglobinaemia w/ prilocaine. May increase risk of ventricular arrhythmias w/ amiodarone. May increase dofetilide-induced QT prolongation. May increase risk of dapsone toxicity. May increase risk of crystalluria w/ methenamine. May increase serum rifampicin levels. Enhanced effects of acenocoumarol and warfarin. Enhanced effect of sulfonylureas. May prolong the half-life of phenytoin. May increase risk of megaloblastic anaemia w/ pyrimethamine given in doses of >25 mg wkly. May increase plasma concentrations of lamivudine, zidovudine and zalcitabine. Increased plasma concentrations w/ procainamide and/or amantadine. May increase risk of haematological toxicity w/ mercaptopurine and azathioprine. May increase digoxin levels. Increased risk of thrombocytopenia w/ diuretics. Potassium aminobenzoate may inhibit the effects of sulfonamides. Concomitant use w/ ciclosporin following renal transplantation may result to reversible deterioration of renal function.Potentially Fatal: Increased risk of fatal agranulocytosis w/ clozapine. Concomitant use w/ leucovorin for the treatment of P. jiroveci in HIV positive patients may result to treatment failure and excess mortality.
Malaysia
